Factors associated with prescription of ARV generics by physicians.

<p>Factors associated with prescription of ARV generics by physicians.</p

Reasons for physician's refusal (N = 138) associated with patient's refusal to use ARV generics.

<p>Reasons for physician's refusal (N = 138) associated with patient's refusal to use ARV generics.</p

Factors associated with acceptance of ARV generics by patients.

<p>Factors associated with acceptance of ARV generics by patients.</p

Factors associated with acceptance of generics <i>per se</i> by patients.

<p>Factors associated with acceptance of generics <i>per se</i> by patients.</p

Patients demographic and medical characteristics (N = 556).

<p>Patients demographic and medical characteristics (N = 556).</p

Longitudinal follow-up of HIV-1 DNA level during the ANRS 139 TRIO Trial.

<p>Longitudinal follow-up of HIV-1 DNA level during the ANRS 139 TRIO Trial.</p

Assessment of model calibration: Observed (Kaplan Meier, black) versus predicted (Cox, gray) survival curves.

<p>Assessment of model calibration: Observed (Kaplan Meier, black) versus predicted (Cox, gray) survival curves.</p

Baseline characteristics of the 1,415 PLHIV aged 60 years or more from the Dat’AIDS cohort.

<p>Baseline characteristics of the 1,415 PLHIV aged 60 years or more from the Dat’AIDS cohort.</p

Five-year Kaplan-Meier survival probabilities among each risk group.

<p>Five-year Kaplan-Meier survival probabilities among each risk group.</p

Model discrimination: Hazard ratio across risk groups.

<p>Model discrimination: Hazard ratio across risk groups.</p